Home > Uncategorized > HOPE 3

HOPE 3

The HOPE3 investigators published the results of the randomized clinical trial of blood pressure lowering (candesartan-hydrochlorothiazide), cholesterol lowering (with rosuvastatin) or both in patients with intermediate risk but no cardiovascular disease. The combined treatment and the cholesterol lowering therapy were associated with reduction in the primary end-point and component adverse cardiovascular events. Blood pressure alone was not associate with reduction in cardiovascular events. Subgroup analysis suggested there may be a beneficial effect in patients with baseline hypertension.

 

Blood Pressure Lowering and Cholesterol Lowering

bc01

 

bc02

 

Blood Pressure Lowering 

hbp01hbp02hbp02_001

Cholesterol Lowering

cl01cl02

Advertisements
Categories: Uncategorized
  1. No comments yet.
  1. No trackbacks yet.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: